A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/2020/QMS/60595
NMA SSA Reference Number: SSA/60595/MonH-2020-209798(v1)
Monash Health Reference: RES-20-0000-244X
Effective start/end date7/05/206/05/25


  • Clinical trial
  • phase 3 study
  • treatment efficacy
  • treatment safety
  • leukemia